

Substitute for form 1449B/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

February 5, 2008

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3506.1000-002APPLICATION NO.
10/757,364FIRST NAMED INVENTOR
Steven B. LandauFILING DATE
January 13, 2004EXAMINER
Yong Soo ChongCONFIRMATION NO.
3343GROUP
1617**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AC7	6,194,382	02-27-2001	Crain, <i>et al.</i>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX5	Wu, Y., <i>et al.</i> , "Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor with 5-HT ₁ Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats," <i>Jpn J of Pharmacology</i> , 83, pp. 31-38 (2000).
AY5	Ishigooka, Jr., <i>et al.</i> , "Serotonin-Noradrenaline Reuptake Inhibitors(SNRIs)," <i>Nippon Rinsho</i> , 59, pp. 1523-9, (2001) - Abstract Only.
AZ5	Spiller, R., "Pharmacotherapy: Non-Serotonergic Mechanisms," <i>Gut</i> , 51, Suppl, i87-i90 (2002).

EXAMINER /Yong Chong/	DATE CONSIDERED 03/11/2008
--------------------------	-------------------------------

784516_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./